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Abstract: Background
The REACH-HF (Rehabilitation EnAblement in CHronic Heart Failure) trial found that
the REACH-HF home-based intervention resulted in a clinically meaningful
improvement in disease-specific health-related quality of life in patients with reduced
ejection fraction heart failure (HFrEF). The aim of this study was to assess the long-
term cost-effectiveness of the addition of REACH-HF intervention or home-based CR
to usual care compared to usual care alone in patients with HFrEF.
Design and methods
A Markov model was developed using a patient lifetime horizon and integrating
evidence from the REACH-HF trial, a systematic review/meta-analysis of randomised
trials, estimates of mortality and hospital admission and UK costs at 2015/6 prices.
Taking a UK National Health and Personal Social Services perspective we report the
incremental cost per quality-adjusted life-year (QALY) gained, assessing uncertainty
using probabilistic and deterministic sensitivity analyses.
Results
In base case analysis, the REACH-HF intervention was associated with per patient
mean QALY gain of 0.30 and an increased mean cost of £126 compared with usual
care, resulting in a cost per QALY of £415. Probabilistic sensitivity analysis indicated a
77% probability that REACH-HF is cost effective versus usual care at a threshold of
£20,000 per QALY. Results were similar for home-based CR versus usual care.
Sensitivity analyses indicate the findings to be robust to changes in model assumptions
and parameters
Conclusions
Our analyses indicate that the addition of the REACH-HF intervention and home-based
CR programmes are likely to be cost-effective treatment options versus usual care
alone in patients with HFrEF.
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Abstract 
Background: The REACH-HF (Rehabilitation EnAblement in CHronic Heart Failure) trial 
found that the REACH-HF home-based cardiac rehabilitation (CR) intervention resulted in a 
clinically meaningful improvement in disease-specific health-related quality of life in patients 
with reduced ejection fraction heart failure (HFrEF). The aims of this study werewas to 
assess the long-term cost-effectiveness of the addition of REACH-HF intervention or home-
based CR to usual care compared to usual care alone in patients with HFrEF. 
Design and methods:  A Markov model was developed using a patient lifetime horizon and 
integrating evidence from the REACH-HF trial, a systematic review/meta-analysis of 
randomised trials, estimates of mortality and hospital admission and UK costs at 2015/6 
prices. Taking a UK National Health and Personal Social Services perspective we report the 
incremental cost per quality-adjusted life-year (QALY) gained, assessing uncertainty using 
probabilistic and deterministic sensitivity analyses.   
Results:  In base case analysis, the REACH-HF intervention was associated with per 
patient mean QALY gain of 0.230 and an increased mean cost of £400126 compared with 
usual care, resulting in a cost per QALY gained of £1,720415. Probabilistic sensitivity 
analysis indicated a 787% probability that REACH-HF is cost effective versus usual care at a 
threshold of £20,000 per QALY gained. Results were similar for home-based CR versus 
usual care. Sensitivity analyses indicate the findings to be robust to changes in model 
assumptions and parameters 
Conclusions: Our cost-utility analyses indicate that the addition of the REACH-HF 
intervention and home-based CR programmes are likely to be cost-effective treatment 
options versus usual care alone in patients with HFrEF.    
 
Key words: cardiac rehabilitation, health-related quality of life, heart failure, home-based, 
cost-effectiveness, decision model   
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Introduction 
Heart failure with reduced ejection fraction (HFrEF) represents a major health issue and is 
associated with considerable morbidity and mortality. HF as primary diagnosis accounts for 
1-2% of the annual healthcare budget in Europe and USA [1]. The global cost economic 
burden of HF is estimated at $US108 billion per annum with hospital admission being a key 
economic driver [2].   
Systematic reviews and meta-analyses of cardiac rehabilitation (CR) for HF have shown 
improvements in health-related quality of life (HRQoL), reductions in re-hospitalisations and 
demonstrated potential cost-effectiveness [3,4]. This existing evidence is based solely 
entirely for on hospital (or centre)-based CR programmes and the economic evaluation data 
is limited in both quantity and quality [3,4]. 
In spite of national and international guidelines recommending CR for HF [5-7], less than 
20% of HF patients in the UK are referred to CR and less than 15% currently participate in 
CR [8-10], prompting calls for alternative more accessible models of CR provision [8]. 
REACH-HF (Rehabilitation EnAblement in CHronic Heart Failure) is a home-based CR 
programme delivered over a 12-weeks by a trained healthcare professional for patients and 
their caregivers. Uniquely the REACH-HF intervention has been co-developed with patients, 
caregivers, and clinicians to include core components of comprehensive CR, i.e., education 
and psychological support, in addition to exercise training [11]. The REACH-HF randomised 
controlled trial compared the addition of REACH-HF intervention to usual care with usual 
care alone in patients with HFrEF across four UK sites [12]. At 12-months, the trial found - 
that the REACH-HF intervention led to a statistically significant and clinically meaningful 
improvement in HRQoL with a reduction in total Minnesota Living with Heart Failure 
Questionnaire score of -5.7 points (95% confidence interval: -10.6 to -0.7) and a non-
significant reduction in the number of patients experiencing one or more hospital admissions 
(odds ratio: 0.56, 95% CI: 0.13 to 2.33). [13]. Having estimated the average cost of REACH-
HF delivery at £418 per patient [13], we sought to assess if the REACH-HF intervention is 
likely to be cost-effective for healthcare payers over the long-term.  
We report the results of a model-based cost-effectiveness analyses that extrapolates the 
findings of REACH-HF trial to estimate the long-term cost-effectiveness of REACH-HF 
intervention. We also report the long-term cost-effectiveness of home-based CR based on a 
meta-analysis of randomised trials.  
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Methods 
This analysis was reported in accord with the Consolidated Health Economic Evaluation 
Reporting Standards (CHEERS) statement [14] and the reference case of the UK National 
Institute for Health and Care Excellence (NICE) [15].  The analyses were conducted from the 
perspective of the UK NHS and Personal Social Services.  We estimated the cost-
effectiveness of REACH-HF plus usual care versus usual care alone and home-based CR 
plus usual care versus usual care alone, based on the estimated incremental cost per 
quality-adjusted life-years (QALY). - a cost-utility analysis. 
 
Study Population 
Data were used from the REACH HF trial [13] where participants with HFrEF were recruited 
from primary and secondary care in 4 UK centres during 2015–2016 and were randomly 
assigned to the REACH-HF intervention plus usual care or usual care alone (current 
standard therapy in the UK for most patients with HF) [12]. In the UK, only a minority of 
patients with HF receive CR and usual care in this trial was a no CR approach that included 
medical management according to national and local guidelines, including specialist HF 
nurse care [13]. Details of REACH-HF intervention are presented elsewhere [12,13]. 
 
Model Structure  
Consistent with the economic evaluation literature in HF [16], a Markov cohort model 
(eFigure 1) was developed that captured the impact onf hospital admissions, and a related 
increase in the mortality rate, for people with HF. In this case a cohort Markov model was 
considered appropriate since this estimates the average effect of the intervention on 
morbidity, mortality, cost and HRQoL. The model uses a lifetime horizon (follows patients 
from a starting age of 78 to age 100) and costs and QALYs were discounted at 3.5% [15]. 
The model consisted of three primary health states: (1) HF with no HF-related hospital 
admission, (2) HF with HF-related hospital admission, and (3) death.  The model uses a one-
month cycle length, in order to capture the effects of hospital admission events which are 
short term events but may recur several times in a year. Tunnel states are used in the model 
to reflect an increased mortality risk in the period (1 to 38 months) after hospital 
admission/discharge. Patients begin in a stable HF health state (HF with no HF-related 
hospitalisation). From this state, patients can either remain in the same state, or experience 
an HF-related hospitalisation or death. If the patients experience an HF-related 
hospitalisation, they automatically progress to the first of 38 post-hospitalisation tunnel 
states, where they will progress one state each month until month 38 post-hospitalisation, 
when they will return to the HF with no HF-related hospitalisation state. During the tunnel 
states, patients can also experience an additional hospitalisation or death at any time. , and 
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the model uses the patient lifetime duration to estimate and compare the costs and QALYs 
for patients receiving REACH-HF or home-based CR. The model was developed in Microsoft 
Excel and programmed in Visual Basic for Applications. 
 
Model inputs 
The model parameters and assumptions about transitions between health states are outlined 
in Table 1.  
CR Effectiveness 
We used data from REACH-HF trial for the difference in risk of hospital admission (odds 
ratio: 0.56, 95% CI: 0.13 to 2.33) [13].  We also undertook a meta-analysis that combined 
REACH-HF trial data with two other randomised trials of home-based CR versus no CR 
usual care [17,18] to estimate the pooled risk of hospital admission following home-based 
CR compared to usual care (odds ratio: 0.70, 95% CI: 0.27 to 1.60) (see eFigure 1 for meta-
analysis forest plot and methodology). This reduction in risk was assumed to last for four 
years from the start of the model, after which hospital admission rates are assumed to return 
to baseline. We assessed the impact on estimates of cost-effectiveness of variations in this 
assumption using sensitivity analyses.   
 
Hospital Admissions 
We applied hospital admission data for HF specific admissions from a UK cohort study 
reflective of a UK primary care setting, with patients experiencing both first and subsequent 
hospital admissions [19] (see Table 1). In sensitivity analyses, we tested the robustness of 
model outcomes to changes in hospital admission rates, using data from the UK Eplerenone 
in Mild Patients Hospitalization and Survival Study in Heart Failure  (EMPHASIS) trial [20], 
which provided a lower estimate of admission rates (10% HF-related admissions; 20% all 
cause admissions per annum), and a meta-analysis of randomised trials [21] reporting 
relatively high admission rates (34% HF-related admissions; 85% all cause admission per 
annum).  We used the same admission rate for all patients in the model irrespective of age 
and previous admissions. 
 
Mortality 
Survival parameters in the model are based on a recently published analysis of UK mortality 
rates in The Health Improvement Network (THIN) dataset, 1998-2012 [22], a retrospective 
cohort of 54,313 HF patients aged over 45.  In a sensitivity analysis, we applied the overall 
survival reported by Mohuiddin et al [23] for patients in another large UK cohort, who had 
already experienced a hospital admission for HF and therefore are expected to have a worse 
prognosis. This study showed increased risk for time since admission in people 0-1 months, 
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1-3 months, 3-6 months, 6-12 months, 12-24 months and 24-38 months after admission. The 
reported hazard ratios were applied in the model. 
Mortality rates have been shown to vary with hospital admission and after discharge both in 
trials [24] and in the wider UK HF population  more generally [25] with those in hospital and 
closer to discharge having higher death rates. Following the approach of Thokala et al [26], 
we reflected this in the model using the hazard ratio for all-cause mortality reported by 
Solomon et al [24] for patients within 1 to over 24 months from discharge for their HF 
hospital admission. For hospital mortality, we derived an additional hazard ratio for survival 
for patients in hospital compared to within 30 days of discharge, from the UK HF Audit [25], 
which reports outcomes from data on more than 73% of all English and Welsh HF 
admissions. We calibrated the baseline mortality rate so that the overall survival curves 
generated by the model matched the survival curves based on parameters taken from the 
THIN analysis [21]. We conservatively assumed that the hazard ratio of death for 
subsequent hospital admissions was the same as for the first hospital admission. We 
assumed that survival followed an exponential curve which has previously been shown to 
provide a good fit in this population [23,27]. 
 
Costs 
Costs were included in pounds sterling using the 2015/16 price year. The following costs 
were considered: (i) home-based CR, (ii) costs associated with HF hospital admission, (iii) 
costs associated with other cause hospital admission, and (iv) primary and secondary usual 
health care costs (excluding hospital admission) associated with HF (see Table 1).  For 
intervention cost we use the UK NHS tariff for CR of £477/patient) [28] and the estimated 
cost for delivery of the REACH-HF intervention of £418/patient [13]. This cost was applied to 
all patients at the start of the model.  Ongoing costs for usual care for HF, primary care, 
secondary care, Accident & Emergency department attendances and drug costs, are 
included for time spent in the HF non-hospital admission state (£815/patient per year), 
informed by UK national data for HF and the THIN dataset, a large UK HF cohort study [22]. 
The cost for hospital admission is based on data from the English NHS National Schedule of 
Reference Costs 2015/16 [28], for HF hospital admission we use a weighted average cost of 
a single hospital stay for the health resource groups (HRGs) EB03A to D. The cost of non-
HF hospital admissions is a background cost in each cycle of the model, where patients are 
alive with HF. We discounted costs and QALYs at an annual rate of 3.5% in accord the NICE 
reference case [15].  
 
Health state values 
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We calculated QALYs by multiplying the health value for the state by the time spent in that 
state.  We use data from Systolic Heart failure treatment with the inhibitor ivabradine Trial 
(SHIFT) to inform health state values, applying a health state value of 0.736 for the HF 
health state, and a reduction (decrement) of 0.084 where people experience a HF related 
hospital admission [30].  For non-HF hospital admissions, we apply a decrement of 0.032 for 
events.  The impact of hospital events on health state values is applied for the one-month 
cycle of hospital admission after which individuals were assumed to return to baseline 
values.  Data from the SHIFT trial, was considered to be the most appropriate for our model 
given the reporting of EQ-5D data for the HF state and separately for a HF specific hospital 
admission.   
 
Analysis 
We present deterministic estimates of the cost per QALY gained and use probabilistic 
sensitivity analysis (PSA) and the incremental net monetary benefit (iNMB) approach [31,32] 
to address uncertainty around the results. The iNMB approach uses parameters 
representing the maximum amount that the Payer (i.e. NHS) is ‘willing to pay’ to gain one 
QALY. We conservatively used the lower NICE threshold value of £20,000 per QALY gained 
in calculating iNMB [15]. An iNMB value > 0 would indicate that the intervention (home 
based CR) is cost-effective. The cost-effectiveness acceptability curve (CEAC) to 
demonstrates how the willingness-to-pay threshold affects the probability that the 
intervention is considered cost-effective [32]. Monte Carlo simulation was used to draw a 
randomly selected estimate of each model parameter from the distributions described in 
Table 1 and to calculate the iNMB. Beta distributions represent the uncertainty in the 
probability parameters (mortality, hospital admission) and parameters for health state values 
because these values are typically bounded at zero and one.  Log-normal distributions were 
used to estimate uncertainty in hazard rates and ratios. We used 5,000 iterations to 
empirically estimate the uncertainty surrounding the mean iNMB.  
The key element of structural uncertainty identified was the use of increasing HF-related 
mortality rates during admission and after discharge from hospital for an HF-related event. 
This mechanism allows any reductions in admission rate brought about by the intervention to 
reduce overall mortality in the cohort, with related cost savings and QALY gains estimated. 
To test how sensitive the results are to the inclusion of this element of model structure we 
included a sensitivity analysis which uses a base mortality rate (from the THIN cohort [22]) 
for all patients at all times, regardless of hospital admission (SA1). 
In addition,  we included further deterministic analyses to test how sensitive the results were 
to the choice of parameter as follows: the lowest hospital admission rate from trials identified 
as sources of HF-specific admission (0.88% probability of admission per month, based on 
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the  Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure 
(EMPHASIS) trial [20] (SA2); the higher hospital admission rate from a large meta-analysis 
of trials (2.83% probability of admission per month [21] (SA3); survival based on previously-
admitted patients in the large combined data in Hospital Episode Statistics (HES) and Office 
of National Statistics (ONS) dataset [23] (SA4); lower mean intervention cost of £204/patient, 
based on the lower bound of the 95% confidence interval around estimated cost for REACH-
HF intervention (SA5); higher mean intervention cost of £730, based on the upper bound of 
the 95% confidence interval around estimated cost for the REACH-HF intervention [13]; and 
assumption for home-based CR effect duration, at 2 years (SA7).  
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Results 
Base-case analysis 
REACH-HF intervention 
Over the HFrEF patient lifetime, compared to usual care alone, the addition of REACH HF 
intervention was more costly (mean £400126/patient) and more effective (mean QALY 
0.230) with an estimated incremental cost effective ratio of £1720415/QALY (Table 2). There 
was a 787% probability that REACH-HF was cost-effective at willingness to pay threshold of 
£20,000/QALY gained (eFigure 3a). 
Home-based CR  
The estimated mean gain in QALYs for home-based CR compared to usual care was 
0.1620, and the estimated mean incremental cost is £383206/patient over the lifetime, giving 
an estimated incremental cost ratio of per £2,4131,029 per QALY (Table 2).  There was 
735% probability that home-based CR was cost-effective compared to usual care, at 
£20,000/QALY gained (eFigure 3b).  
 
Sensitivity analyses 
Sensitivity analyses (eTables 1a and 1b) indicate the base case analyses to be robust and 
not sensitive to changes in key structural assumptions in the modelling framework or key 
input parameters (i.e. mortality effect of hospital admission, probability of hospital admission, 
probability of mortality, home-based CR, duration of treatment effect) for both REACH-HF 
and home-based CR. Removing the increase in risk of mortality after hospital admission 
(SA1) resulted, in home-based CR dominating usual care, with a reduction in costs (cost 
saving) and no difference QALYs.  In this scenario, although QALY gains are reduced, the 
costs associated with home-based CR also reduce due to the absence of an extended 
period of life expectancy and the absence of the additional costs associated with extending 
lives in the home-based CR group.   
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Discussion 
Our estimates suggest that the addition of REACH-HF intervention home-based CR to usual 
care was cost-effective compared to usual care alone in patients with HFrEF at a cost of 
£1730415/QALY and a 787% likelihood of being cost-effective at the willingness to pay 
threshold of £20,000 per QALY gained used by policymakers in UK and many developed 
health-care economies [15,33]. Our cost-effectiveness estimates for other home-based CR 
programmes were similar. Our results were mainly driven by a reduction in HF-related 
hospitalisations with CR.  
Two recent systematic reviews of cost-effectiveness of CR have been published [4,34]. To 
the best of our knowledgeBased on the results of these reviews, this is first published full 
economic evaluation of a comprehensive  a specific home-based programme (REACH-HF) 
and home-based CR programmes more broadly in patients with HF. However, our findings 
are consistent with previously economic evaluations in HF comparing centre-based CR to no 
CR control [4]. Using extrapolated outcome survival data from a single centre randomised 
controlled trial, Georgiou and colleagues reported an incremental cost-effectiveness ratio of 
US$2500 per life year gained for exercise training programme at a 10-year time horizon 
based on US healthcare perspective [354]. Using a variety of modelling assumptions and 
data at 2.5 years follow up from the large HF-ACTION trial undertaken across 82 centres 
across United States, Canada, and France, Reed et al estimated that the cost-effectiveness 
of exercise training could vary from dominant (cost saving and more QALYs gained) to 
US$43,141/QALY [365]. Based on data from exercise-based CR programme in Colombia, 
using modelling Rincón et al estimated an incremental cost per QALY of US$1,065/QALY at 
5 years [376]. Finally, a Markov model-based analysis by Kühr et al reported a cost per 
QALY of 29,498 international dollars for a hypothetical cohort of HF patients attending 
outpatient CR programme from the perspective of the Brazilian Public Healthcare System 
over a 10-year time horizon [387]. Notwithstanding the challenge of directly comparing costs 
across international jurisdictions and whilst these incremental cost effectiveness ratios vary 
in their magnitude, they have broadly been interpreted by study authors as demonstrating 
CR to be a cost-effective strategy in patients with HFrEF.  
Although not recruiting HF patients, the recently published FIT@Home study also showed 
home-based CR can be a cost-effective strategy [39].  This study randomised 90 low to 
moderate risk patients following an acute coronary syndrome or revascularisation to three 
months of either home-based training with telemonitoring guidance or centre-based training. 
Average healthcare costs were lower in the home-based group (€437 per patient) and had 
probability of being cost-effective of 97% and 75% at willingness-to-pay of €0 and €100,000 
per QALY, respectively.  
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Strengths and limitations 
This study usesd cost and outcome data from a high quality multicentre randomised 
controlled trial of REACH-HF in patients with HFrEF with multiple comorbidities reflective of 
the clinical setting [13]. The use of Markov modelling overcomes the limitations of a within 
trial economic evaluation, allowing the modelling of costs and outcomes over the longer term 
of patient lifetime and the assessment of the long-term cost effectiveness beyond the trial 
period. The use of longer time-horizon is also more compatible with the chronic nature of HF 
and in accord with NICE methodology guidance [15]. We use high quality data on mortality 
from a large cohort study consistent with the setting for our economic analysis.  Given the 
variation of hospital admission data, we use a UK dataset in our base case analysis. 
However, use was made of alternative data sources were used in sensitivity analyses.   
A key limitation was that the REACH-HF trial was not powered to detect differences in 
hospitalisations between arms. However, we sought to overcome this by undertaking a 
meta-analysis where we included data from two other randomised trials that tested different 
versions of home-based CR. Furthermore, our probabilistic sensitivity analysis explicitly took 
account of the uncertainty in the data inputs to the model. Nevertheless, that the overall 
number of hospitalisations was low (30 events), we acknowledge the need for additional 
future trials of CR need to consistently collect ing and report this the outcome of patient 
hospitalisation. Furthermore, our probabilistic sensitivity analysis explicitly took account of 
the uncertainty in the data inputs to the model. We used a simple Markov modelling 
approach, and whilst this approach is consistent with the wider literature on economic 
models in HF, we acknowledge it assumes no additional impact from multiple admissions. 
Whereas in real life patients may suffer from worsening HRQoL after further subsequent 
hospital stays. This conservative assumption may have led us to have underestimated the 
cost-effectiveness of REACH-HF and home-based CR.  We use HF-related hospital 
admissions as the main event of interest in the assessment of home-based CR. The 
absence of any specific modelling of effects on other (non-HF specific) cause of hospital 
admissions may be a limitation of the modelling, although is also likely to a conservative 
assumption as CR may positively impact on the risk of admissions due to other 
cardiovascular related events, such as myocardial infarction or stroke.  
 
Clinical implications  
This cost-utility analysis indicates that the REACH-HF intervention and home-based CR 
programmes are likely to be cost-effective for patients for HFrEF. These economic results 
have considerable policy relevance given current low levels of uptake of CR for HF across 
international healthcare systems [4038]. In order to improve CR participation there have 
been calls for the development of CR programmes that provide an alternative to supervised 
Formatted: Highlight
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outpatient programmes, such as home-based programmes [8,9,4139]. The results of this 
analysis are therefore timely and show that home-based CR programmes provide a cost-
effective alternative use of healthcare resources. The systematic review of home versus 
centre-based CR by Wong et al concluded that as costs and outcomes of home-based 
versus supervised centre-based CR were no different, the choice of the mode of delivery 
(home- versus centre-based) should be left to healthcare providers and patients [420]. This 
is further reinforced by the recently updated UK clinical guidelines for the management of HF 
that patients, which recommend that patients should be offered CR “in a format and setting 
(at home, in the community or in the hospital) that is easily accessible for the person” [7].  
Formatted: Highlight
Formatted: Highlight
 14 | P a g e  
 
Conclusion 
Over the lifetime of the HFrEF patient, our cost-utility analyses suggest that REACH-HF and 
home-based CR are cost-effective treatment options in the setting of the United Kingdom 
health service. These findings should encourage healthcare providers and purchasers to 
fund home-based CR programmes to improve access and promote participation in CR for 
people with HF and thereby improve the health-related quality of life and morbidity of this 
population.  
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Table 1. Model parameters and assumptions   
Parameter Base case 
value (mean) 
Probabilistic 
distribution 
Standard error Source 
Mortality     
Monthly probability of death* 0.650% Beta  [22] 
RR of death in hospital compared to 30 days of 
discharge 
1.5 Fixed  [25] 
HR of mortality rate 
by months since 
discharge 
≤1 6.18 Lognormal 1.1364 [24] 
>1 4.39 Lognormal 1.1225 
>3 3.54 Lognormal 1.1150 
>6 3.11 Lognormal 1.0978 
>12 2.46 Lognormal 1.0948 
>24 1.93 Lognormal 1.1450 
Hospital admission     
Monthly probability of HF admission 2.04% Beta  [19] 
Monthly probability of other cause admission 1.97% Beta  [19]  
Average length of stay (days) 8 Fixed  [25] 
Intervention effect     
OR for HF admission: REACH-HF 0.56 Lognormal 2.03 [13] 
OR for HF admission: home-based CR  0.70 Lognormal 1.60 Meta-analysis (see Appendix 1) 
Duration of treatment effect 4 years Fixed  Assumption 
Costs (per patient)     
Admission HF £3,87305 FixedGamma  [29] 
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Admission other causes £2,2408 GammaFixed  [20,29]  
Admission all cause £2,901850† FixedGamma  [20,29] 
Ongoing monthly healthcare £968‡ Fixed  [24,29,41-43]   
REACH-HF £418 Fixed  [13] 
Home-based RehabCR £477 Fixed  [28] 
Utilities     
Utility for HF patients at baseline 0.736 Fixed  [30] 
HF hospital admission decrement  -0.084 Beta 0.006 [30] 
Other cause hospital admission decrement  -0.032 Beta 0.005 [30] 
Assumptions     
Usual care was a no CR (either home- or centre-based) approach that included medical management according to national and local 
guidelines, including specialist HF nurse care  
Usual care was assumed to include no use of centre-based CR 
Patients can be admitted for HF during any one-month cycle and probability of admission was fixed for all patients at all times regardless of 
previous admissions. 
First and subsequent HF hospitalisations give the same RR of death compared to no hospitalisation. 
Other causes hospitalisations don’t independently increase risk of death. 
Rate of other causes hospitalisations do not change as a result of treatment allocation 
The cost and QoL impact of being in any of the post-HF hospitalisation states (from 1 to 38+ months after discharge) were assumed to be the 
same 
*At baseline i.e. never hospitalised or >38 months since last hospitalisation 
‡ Based on data for resource use by type, for people with HF: Comprises £384 721 pa for drug costs, £336 pa for A&E attendances, £96 101 pa 
for outpatient appointments and £3020 pa for GP appointments monthly 
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† We estimate a per month cost for non-HF hospital admission based on a weighted average cost across four common types of non-HF admission 
(other CVD, renal function, hyperkalaemia and other), using data on proportions of each admission type reported in the EMPHASIS Trial (Zannad 
et al [20]), combined with unit costs taken from the English National Schedule of Reference Costs 2015/16. 
RR: relative risk, OR: odds ratio; HR: hazard ratio 
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Table 2. Results of cost-effectiveness analyses: REACH-HF intervention and home-based CR vs. usual care  
 Discounted Costs 
£, mean (95% CI) 
Discounte
d QALYs 
mean (95% 
CI) 
ICER 
(£ per QALY 
gained) 
Vs. usual care  
% 
simulation
s  
with iNMB 
> £0 
Usual care alone £1,505113,031 (£1,384412,381 to 
£1,628913,549) 
4.244.26 
(4.05 to 
4.43) 
  
REACH-HF intervention plus usual 
care 
£1,545213,157 (£1,424012,563 to 
£1,678014,396) 
4.474.56 
(3.833.76 
to 4.91) 
£1,721415 7877% 
Home-based CR plus usual care  £1,544413,237 (£1,427812,598 to 
£1,678114,061) 
4.404.46 
(3.893.90 
to 
4.774.79) 
£2,4131,029 7375% 
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Agreement shall be of no further force and effect, and neither you nor the Proprietor nor SAGE will have any obligation 
to the other with respect to the Contribution.  
 
 
General Provisions.  
This Agreement shall be deemed to be a contract made in England and shall be construed and applied in all respects 
in accordance with English law and the parties submit and agree to the jurisdiction of the English courts. 
 
This Agreement may be executed in counterparts each of which shall be deemed the original, all of which together 
shall constitute one and the same Agreement.  A faxed copy or other electronic copy shall be deemed as an original.   
This transaction may be conducted by electronic means and the parties authorize that their electronic signatures act 
as their legal signatures of this Agreement. This Agreement will be considered signed by a party when their electronic 
signature is transmitted. Such signature shall be treated in all respects as having the same effect as an original 
handwritten signature. (You are not required to conduct this transaction by electronic means or use an electronic 
signature, but if you do so, then you hereby give your authorization pursuant to this paragraph.) 
 
No amendment or modification of any provision of this Agreement shall be valid or binding unless made in writing and 
signed by all parties.  
 
This Agreement constitutes the entire agreement between the parties with respect to its subject matter, and 
supersedes all prior and contemporaneous agreements, understandings and representations.  The invalidity or 
unenforceability of any particular provision of this Agreement shall not affect the other provisions, and this Agreement 
shall be construed in all respects as if any invalid or unenforceable provision were omitted.  
 
If any difference shall arise between you and the Proprietor touching the meaning of this Agreement or the rights and 
liabilities of the parties thereto, the same shall be referred to the arbitration of two persons (one to be named by each 
party) or their mutually agreed umpire, in accordance with the provision of the England Arbitration Act 1996 or any 
amending or substituted statute for the time being in force. 
 
 
Consent for Commercial Electronic Messages.  
You hereby provide your express consent for the Proprietor, its affiliates and licensees (expressly including SAGE, 
where SAGE is not the Proprietor), and their respective designees to contact you in connection with any business 
communication or other correspondence. The parties agree that such consent may be withdrawn by you at a later time 
by providing written notice (including by email) to the Proprietor (and/or SAGE if different than the Proprietor). This 
clause shall survive expiration or earlier termination of this Agreement. 
 
 
 
For more information on copyright and permissions and SAGE’s publishing policies (including Ethics & 
Responsibility), please visit the SAGE Journal Author Gateway:  
https://uk.sagepub.com/en-gb/eur/page/journal-author-gateway 
 
SAGE will provide the Corresponding Author of the Contribution with an electronic copy of the Contribution. For 
information about how you may re-use the Contribution, please consult SAGE Journals Permissions: 
https://uk.sagepub.com/en-gb/eur/journals-permissions   
All commercial re-use of the published Contribution should be referred to SAGE. 
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